-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) shareholders have had their patience rewarded with a 35% share price jump in the last month. But the gains over the last month weren't enough to make shareholders whole, as the share price is still down 3.4% in the last twelve months.
Since its price has surged higher, given close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 8x, you may consider CK Life Sciences Int'l. (Holdings) as a stock to avoid entirely with its 49.6x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
The earnings growth achieved at CK Life Sciences Int'l. (Holdings) over the last year would be more than acceptable for most companies. One possibility is that the P/E is high because investors think this respectable earnings growth will be enough to outperform the broader market in the near future. If not, then existing shareholders may be a little nervous about the viability of the share price.
See our latest analysis for CK Life Sciences Int'l. (Holdings)
SEHK:775 Price Based on Past Earnings June 23rd 2022 Although there are no analyst estimates available for CK Life Sciences Int'l. (Holdings), take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.Is There Enough Growth For CK Life Sciences Int'l. (Holdings)?
There's an inherent assumption that a company should far outperform the market for P/E ratios like CK Life Sciences Int'l. (Holdings)'s to be considered reasonable.
If we review the last year of earnings growth, the company posted a terrific increase of 30%. Still, incredibly EPS has fallen 38% in total from three years ago, which is quite disappointing. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.
Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 16% shows it's an unpleasant look.
With this information, we find it concerning that CK Life Sciences Int'l. (Holdings) is trading at a P/E higher than the market. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the recent negative growth rates.
The Bottom Line On CK Life Sciences Int'l. (Holdings)'s P/E
Shares in CK Life Sciences Int'l. (Holdings) have built up some good momentum lately, which has really inflated its P/E. Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
We've established that CK Life Sciences Int'l. (Holdings) currently trades on a much higher than expected P/E since its recent earnings have been in decline over the medium-term. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.
Don't forget that there may be other risks. For instance, we've identified 4 warning signs for CK Life Sciences Int'l. (Holdings) (2 are a bit unpleasant) you should be aware of.
If you're unsure about the strength of CK Life Sciences Int'l. (Holdings)'s business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) shareholders have had their patience rewarded with a 35% share price jump in the last month. But the gains over the last month weren't enough to make shareholders whole, as the share price is still down 3.4% in the last twelve months.
中科生命科學國際(控股)有限公司(HKG:775)股東的耐心得到了回報,股價在過去一個月上漲了35%。但過去一個月的漲幅不足以讓股東們變得完整,因為該公司股價在過去12個月裏仍下跌了3.4%。
Since its price has surged higher, given close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 8x, you may consider CK Life Sciences Int'l. (Holdings) as a stock to avoid entirely with its 49.6x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
由於其股價飆升,考慮到香港近一半的公司的市盈率(P/E)低於8倍,你可以考慮將CK Life Science Int‘l.(Holdings)作為一隻股票,完全避免其49.6倍的市盈率。然而,僅僅從表面上看待市盈率是不明智的,因為可能會有一個解釋,為什麼它如此之高。
The earnings growth achieved at CK Life Sciences Int'l. (Holdings) over the last year would be more than acceptable for most companies. One possibility is that the P/E is high because investors think this respectable earnings growth will be enough to outperform the broader market in the near future. If not, then existing shareholders may be a little nervous about the viability of the share price.
CK生命科學國際(控股)去年實現的收益增長對大多數公司來説都是可以接受的。一種可能性是,市盈率很高,因為投資者認為,這種可觀的收益增長在不久的將來將足以跑贏大盤。如果不是,那麼現有股東可能會對股價的生存能力感到有點緊張。
See our latest analysis for CK Life Sciences Int'l. (Holdings)
查看我們對CK生命科學國際公司的最新分析。
Is There Enough Growth For CK Life Sciences Int'l. (Holdings)?
CK生命科學國際(控股)是否有足夠的增長?
There's an inherent assumption that a company should far outperform the market for P/E ratios like CK Life Sciences Int'l. (Holdings)'s to be considered reasonable.
有一種固有的假設,即一家公司的市盈率應該遠遠超過市場,就像CK Life Science Int.(Holdings)的市盈率被認為是合理的。
If we review the last year of earnings growth, the company posted a terrific increase of 30%. Still, incredibly EPS has fallen 38% in total from three years ago, which is quite disappointing. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.
如果我們回顧一下去年的收益增長,該公司公佈了30%的驚人增長。儘管如此,令人難以置信的是,每股收益比三年前總共下降了38%,這相當令人失望。因此,公平地説,最近的收益增長對公司來説是不可取的。
Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 16% shows it's an unpleasant look.
將這一中期收益軌跡與大盤一年增長16%的預期進行比較,可以看出這是一個令人不快的前景。
With this information, we find it concerning that CK Life Sciences Int'l. (Holdings) is trading at a P/E higher than the market. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the recent negative growth rates.
根據這些信息,我們發現CK生命科學國際(控股)的市盈率高於市場。似乎大多數投資者都忽視了最近糟糕的增長率,並希望該公司的業務前景有所好轉。如果市盈率下降到與最近負增長更一致的水平,現有股東很有可能會讓自己未來感到失望。
The Bottom Line On CK Life Sciences Int'l. (Holdings)'s P/E
CK生命科學國際(控股)市盈率的底線
Shares in CK Life Sciences Int'l. (Holdings) have built up some good momentum lately, which has really inflated its P/E. Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
CK生命科學國際(控股)的股票最近出現了一些良好的勢頭,這確實抬高了其市盈率。一般來説,我們傾向於將市盈率的使用限制在確定市場對公司整體健康狀況的看法上。
We've established that CK Life Sciences Int'l. (Holdings) currently trades on a much higher than expected P/E since its recent earnings have been in decline over the medium-term. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.
我們已經確定,CK生命科學國際(控股)目前的市盈率遠遠高於預期,因為它最近的收益在中期內一直在下降。當我們看到盈利出現倒退,表現遜於市場預期時,我們懷疑股價有下跌的風險,導致高市盈率走低。除非最近的中期狀況明顯改善,否則要接受這些價格是合理的是非常具有挑戰性的。
Don't forget that there may be other risks. For instance, we've identified 4 warning signs for CK Life Sciences Int'l. (Holdings) (2 are a bit unpleasant) you should be aware of.
別忘了,可能還有其他風險。例如,我們已經確定CK生命科學國際(控股)的4個警告標誌(2)你應該意識到這一點。
If you're unsure about the strength of CK Life Sciences Int'l. (Holdings)'s business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
如果你.不確定CK生命科學國際(控股)的業務實力,為什麼不探索我們的互動名單與堅實的業務基本面為其他一些公司,你可能有不及預期的期望。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧